CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback